138 related articles for article (PubMed ID: 27288034)
21. Radiometric vs. agar proportion methods for assessing ethionamide resistance and its clinical effects in multidrug-resistant tuberculosis.
Cimen NO; Arslan Z; Saygi A; Ocak K; Babacan F; Kurutepe M
Int J Tuberc Lung Dis; 2009 Jul; 13(7):907-13. PubMed ID: 19555543
[TBL] [Abstract][Full Text] [Related]
22. Beyond multidrug-resistant tuberculosis in Europe: a TBNET study.
Günther G; van Leth F; Altet N; Dedicoat M; Duarte R; Gualano G; Kunst H; Muylle I; Spinu V; Tiberi S; Viiklepp P; Lange C;
Int J Tuberc Lung Dis; 2015 Dec; 19(12):1524-7. PubMed ID: 26614196
[TBL] [Abstract][Full Text] [Related]
23. Tolerability and efficacy of isoprodian-containing antituberculosis regimens.
Kleeberg HH
S Afr Med J; 1986 Feb; 69(3):161. PubMed ID: 3511545
[No Abstract] [Full Text] [Related]
24. Detection of katG and inhA mutations to guide isoniazid and ethionamide use for drug-resistant tuberculosis.
Bollela VR; Namburete EI; Feliciano CS; Macheque D; Harrison LH; Caminero JA
Int J Tuberc Lung Dis; 2016 Aug; 20(8):1099-104. PubMed ID: 27393546
[TBL] [Abstract][Full Text] [Related]
25. A case of DRESS syndrome induced by the antituberculosis drugs, prothionamide, and para-aminosalycilic acid.
Kim JH; Jang SH; Kim DH; Park S; Kim DG; Jung KS
Ann Allergy Asthma Immunol; 2013 Feb; 110(2):118-9. PubMed ID: 23352532
[No Abstract] [Full Text] [Related]
26. Hypothyroidism due to ethionamide.
McDonnell ME; Braverman LE; Bernardo J
N Engl J Med; 2005 Jun; 352(26):2757-9. PubMed ID: 15987931
[No Abstract] [Full Text] [Related]
27. [Late results of treatment of patients with drug resistant bacilli with ethionamide and other antitubercular agents].
Pregowski W; Zagórecka A
Gruzlica; 1968 Oct; 36(10):1047-9. PubMed ID: 5715457
[No Abstract] [Full Text] [Related]
28. Hepatitis associated with prothionamide for treatment of multidrug-resistant tuberculosis.
Hsu HL; Bai KJ; Chiang YC; Lin SJ; Yu MC
J Formos Med Assoc; 2010 Dec; 109(12):923-7. PubMed ID: 21195892
[TBL] [Abstract][Full Text] [Related]
29. [Ethionamide in the treatment of patients infected with drug resistant bacilli].
Pregowski W; Zagórecka A
Pol Tyg Lek; 1966 May; 21(22):833-7. PubMed ID: 5962181
[No Abstract] [Full Text] [Related]
30. Ethionamide-induced hypothyroidism.
Dutta BS; Hassan G; Waseem Q; Saheer S; Singh A
Int J Tuberc Lung Dis; 2012 Jan; 16(1):141. PubMed ID: 22236862
[No Abstract] [Full Text] [Related]
31. Ethionamide.
Tuberculosis (Edinb); 2008 Mar; 88(2):106-8. PubMed ID: 18486043
[No Abstract] [Full Text] [Related]
32. [A case of pulmonary multiresistant Mycobacterium bovis tuberculosis in Madagascar].
Ramarokoto H; Andrianasolo D; Rasolonavalona T; Ramaroson F; Razafitsiarovana I; Vincent V; Ratsimba L; Rasolofo Razanamparany V
Arch Inst Pasteur Madagascar; 2003; 69(1-2):37-40. PubMed ID: 15678814
[TBL] [Abstract][Full Text] [Related]
33. Gynecomastia in multi-drug resistant tuberculosis - ethionamide the villain.
Deokar K; Shaikh AL; Chawla G
Adv Respir Med; 2020; 88(2):162-163. PubMed ID: 32383471
[No Abstract] [Full Text] [Related]
34. The treatment of tuberculosis.
Springett VH
Practitioner; 1975 Oct; 215(1288):480-6. PubMed ID: 53832
[No Abstract] [Full Text] [Related]
35. [Effect of cycloserine, ethionamide, and ethoxyd on liver function in pulmonary tuberculosis].
Baĭl'dinova IM
Ter Arkh; 1971 Jan; 43(1):101-4. PubMed ID: 5574526
[No Abstract] [Full Text] [Related]
36. In vitro physicochemical characterization and short term in vivo tolerability study of ethionamide loaded PLGA nanoparticles: potentially effective agent for multidrug resistant tuberculosis.
Kumar G; Malhotra S; Shafiq N; Pandhi P; Khuller GK; Sharma S
J Microencapsul; 2011; 28(8):717-28. PubMed ID: 21985449
[TBL] [Abstract][Full Text] [Related]
37. Multi-drug therapy in leprosy: an effective method of control.
Indian J Lepr; 1984; 56(1):102-12. PubMed ID: 6548238
[TBL] [Abstract][Full Text] [Related]
38. Serum pharmacokinetics of antimycobacterial drugs in patients with multidrug-resistant tuberculosis during therapy.
Yew WW; Cheung SW; Chau CH; Chan CY; Leung CK; Cheng AF; Wong CF
Int J Clin Pharmacol Res; 1999; 19(3):65-71. PubMed ID: 10761535
[TBL] [Abstract][Full Text] [Related]
39. Susceptibility tests to second line drugs and re-treatment of tuberculosis revisiting early experiences.
de Kantor IN; Barrera L
Medicina (B Aires); 2007; 67(3):231-7. PubMed ID: 17628909
[TBL] [Abstract][Full Text] [Related]
40. Treatment outcomes of rifampin-sparing treatment in patients with pulmonary tuberculosis with rifampin-mono-resistance or rifampin adverse events: A retrospective cohort analysis.
Park S; Jo KW; Lee SD; Kim WS; Shim TS
Respir Med; 2017 Oct; 131():43-48. PubMed ID: 28947041
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
